Investigators introduced an agarose microwell platform designed for patient-derived organoid-based tumor and tumor microenvironment models, enabling rapid drug screening and resistance studies with small sample volumes.
[Lab On A Chip]
Deciphering Fibroblast-Induced Drug Resistance in Non-Small Cell Lung Carcinoma through Patient-Derived Organoids in Agarose Microwells
